MSD Animal Health Announces 2020 High-Quality Pork — Precision Farming Award Recipient
Winner Granted Funds to Implement Applied Project in Precision Farming in Swine
MADISON, N.J., December 2, 2020 – MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is proud to announce that the 2020 High-Quality Pork — Precision Farming Award has been granted to Tami Brown-Brandl, Ph.D., professor of biological systems engineering at the Institute of Agriculture and Natural Resources at the University of Nebraska-Lincoln. The award, which grants up to US$200,000 towards project implementation with an interested customer in 2021, was created to encourage technological innovation to solve real-world technology challenges in the swine industry.
Dr. Brown-Brandl and her team’s project, titled “Next-Generation Grow-Finish Swine Health and Growth Monitoring,” validated the efficacy of an innovative radio-frequency identification (RFID) technology and depth cameras to monitor feeding/drinking behaviors and weight gain in pigs to accurately detect anomalous events as well as acute and chronic illnesses. Such data provides critical information in real time that would help the farmer make better pig management intervention decisions, potentially leading to substantial economic benefits for pig producers worldwide. As a result of the study, the monitoring system and other technology solutions will be further developed to improve early illness detection and market weight estimation, ultimately improving precision animal management for the swine industry.
“We are pleased to recognize Dr. Brown-Brandl for her innovative approach to next-generation swine health and growth monitoring, which has the potential to advance pig farming and the health and well-being of swine,” said Rika Jolie, DVM, Ph.D., MBA, global swine lead, MSD Animal Health. “As a company, we strive to extend the range of technological solutions we can provide our customers, so we are proud to offer the High-Quality Pork—Precision Farming Award to help identify science-based technology solutions to industry challenges.”
Dr. Brown-Brandl was selected through a competitive process that included a diverse pool of candidates from around the world, including Africa, Asia Pacific, Europe, North America and South America. Entrants presented a wide array of projects, ranging from product convenience to workforce safety and improved animal handling.
“This award is truly an honor – what an exciting time to be working in animal agriculture,” said Dr. Brown-Brandl. “The producers, scientists and engineers working in the area of precision animal management are truly shaping the future of animal production. I appreciate MSD Animal Health joining us in helping lead that charge.”
About MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com/ or connect with us on LinkedIn and Twitter.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2018 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).